# Medical research in metabolic and liver diseases > Live situation record from CLSTR: https://clstr.news/situations/medical-research-in-metabolic-and-liver-diseases > Updated: 2026-10-04T02:48:32.000Z. Sources: 5. Developments: 2. Medical research has identified new potential pathways for treating metabolic diseases, specifically focusing on liver health and obesity. Researchers at Cedars-Sinai have identified the UBE2N enzyme as a potential target for metabolic dysfunction-associated steatohepatitis (MASH). Studies indicate that UBE2N levels decline as liver disease progresses from MASLD to MASH. The enzyme appears to protect the liver by facilitating mitophagy, a process where damaged mitochondria are cleared. When UBE2N is deficient, the protein p62 accumulates incorrectly, contributing to inflammation, fat accumulation, and scarring. In parallel, advancements in obesity treatment have been reported through the phase III SYNCHRONIZE-1 clinical trial. Results published in the New England Journal of Medicine highlight the experimental drug Survodutide, developed by Boehringer Ingelheim and Zealand Pharma. As a dual agonist for GLP-1 and glucagon receptors, Survodutide aims to reduce appetite and influence metabolism differently than first-generation GLP-1 agonists. ## Timeline ### 2026-10-04: Medical research advances in liver disease and obesity treatments New research explores the role of the UBE2N enzyme in preventing liver fibrosis and examines Survodutide, an experimental dual agonist drug for obesity and metabolic regulation. 3 sources. https://clstr.news/cluster/medical-research-advances-in-liver-disease-and-obesity-treatments ### 2026-10-03: UBE2N enzyme identified as potential target for MASH liver disease A Cedars-Sinai study identifies the UBE2N enzyme as a potential target for treating MASH, showing that restoring enzyme levels in mice reduces liver inflammation, fat, and scarring. 2 sources. https://clstr.news/cluster/ube2n-enzyme-identified-as-potential-target-for-mash-liver-disease --- Cite as: Medical research in metabolic and liver diseases. CLSTR, https://clstr.news/situations/medical-research-in-metabolic-and-liver-diseases